Long-term Safety of Lumacaftor/Ivacaftor in Participants With Cystic Fibrosis Who Are Homozygous for F508del and 12 to <24 Months of Age at Treatment Initiation
Clinical trial NCT04235140 · COMPLETED
Trial details
- NCT number
- NCT04235140
- Sponsor
- Vertex Pharmaceuticals Incorporated
- Status
- COMPLETED
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2020-02-24
- Primary completion
- 2023-08-22
- Enrollment
- 52
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.